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Abstract
The disease processes underlying inherited retinal disease are complex and are not completely understood. Many of the
corrective gene therapies designed to treat diseases linked to mutations in genes specifically expressed in photoreceptor
cells restore function to these cells but fail to stop progression of the disease. There is growing consensus that effective
treatments for these diseases will require delivery of multiple therapeutic proteins that will be selected to treat specific
aspects of the disease process. The purpose of this study was to design a lentiviral transgene that reliably expresses all of
the proteins it encodes and does so in a consistent manner among infected cells. We show, using both in vitro and in vivo
analyses, that bicistronic lentiviral transgenes encoding two fluorescent proteins fused to a viral 2A-like cleavage peptide
meet these expression criteria. To determine if this transgene design is suitable for therapeutic applications, we replaced
one of the fluorescent protein genes with the gene encoding guanylate cyclase -1 (GC1) and delivered lentivirus carrying
this transgene to the retinas of the GUCY1*B avian model of Leber congenital amaurosis – 1 (LCA1). GUCY1*B chickens carry
a null mutation in the GC1 gene that disrupts photoreceptor function and causes blindness at hatching, a phenotype that
closely matches that observed in humans with LCA1. We found that treatment of these animals with the 2A lentivector
encoding GC1 restored vision to these animals as evidenced by the presence of optokinetic reflexes. We conclude that 2A-
like peptides, with proper optimization, can be successfully incorporated into therapeutic vectors designed to deliver
multiple proteins to neural retinal. These results highlight the potential of this vector design to serve as a platform for the
development of combination therapies designed to enhance or prolong the benefits of corrective gene therapies.
Citation: Verrier JD, Madorsky I, Coggin WE, Geesey M, Hochman M, et al. (2011) Bicistronic Lentiviruses Containing a Viral 2A Cleavage Sequence Reliably Co-
Express Two Proteins and Restore Vision to an Animal Model of LCA1. PLoS ONE 6(5): e20553. doi:10.1371/journal.pone.0020553
Editor: Amy C.Y. Lo, The University of Hong Kong, Hong Kong
Received December 3, 2010; Accepted May 4, 2011; Published May 27, 2011
Copyright:  2011 Verrier et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: This research was supported by NIH grants EY11388 (SSR) and an NIH Vision Core Grant EY08571 (http://www.nei.nih.gov/). The funders had no role in
study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: rowland@mbi.ufl.edu
Introduction
Development of effective, long-lasting therapies for the
treatment of progressive autosomal recessive retinal diseases that
cause blindness early in life remains a challenge. Many of these
diseases are caused by mutations in genes expressed exclusively in
photoreceptor cells that disrupt their structure and function. There
have been numerous studies showing that the effects of these
mutant genes on photoreceptor cells can be reversed by delivering
a normal copy of the mutated gene to these cells; however, in most
cases these corrective gene therapies only provide a temporary
reprieve from photoreceptor degeneration and the ensuing
blindness that defines these diseases [1–3]. Because many of these
aggressive photoreceptor diseases cause blindness early in life, it is
desirable to develop treatment strategies that provide lifelong
therapeutic benefits.
The most straightforward approach to achieving this treatment
goal is to ensure that every photoreceptor in the diseased retina
receives a copy of the corrective gene required to restore function
to the cell before it has irreversibly committed itself to die. This
strategy, while biologically sound, is currently unrealistic given the
limitations of existing gene delivery methods. An alternate strategy
to achieve this goal is suggested by examining the long-term
therapeutic successes recently achieved using corrective gene
therapy to treat Leber congenital amaurosis – 2 (LCA2) [4–7].
The gene mutated in LCA2 encodes retinal pigment epithelium-
specific protein 65-kDa (RPE65), a protein that is specifically
expressed in pigment epithelial cells and is critical for processing
the vitamin A chromophore that photoreceptors need to
regenerate their visual pigments following light stimulation [8,9].
In the absence of this chromophore, photoreceptors are unable to
respond to light and eventually degenerate [9]. In human retina,
the ratio of retinal pigment epithelial cells to photoreceptor cells is
approximately 1:22 [10], one pigment epithelial cell supporting
the function of about 22 photoreceptors. Thus, for every retinal
pigment epithelial cell treated, approximately 22 photoreceptor
cells regain function, a relationship that essentially amplifies the
therapeutic benefits of the RPE65 therapy. In addition to
amplifying the effect of RPE65 therapy, the relationship between
the pigment epithelium and the adjacent photoreceptors also
serves to minimize the number of untreated photoreceptor cells
within treated areas which could positively influence the efficacy of
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survival of treated cells.
Unfortunately, unlike LCA2 therapies, the effects of corrective
gene therapies designed to restore function to photoreceptors
affected by genetic mutations located in photoreceptor genes are
not amplified by retinal physiology or structure. Thus, developing
methods to maximize the number of photoreceptor cells that
receive corrective gene therapy remains a priority in developing
treatments for these diseases. In addition to increasing the
numbers of treated photoreceptors, can we prolong survival of
these cells? One method to accomplish this would be to pair
delivery of the corrective gene with delivery of additional
therapeutic proteins that would enhance survival of photorecep-
tors. The results of our work on LCA1 have led us to consider this
possible treatment route.
LCA1 is caused by null mutations in the GUCY2D gene
(NC_000017.10) that encodes guanylate cyclase-1 (GC1), an
enzyme that is expressed in photoreceptor cells [11]. GC1 plays a
critical role in the ability of photoreceptor cells to recover from
light stimulation [12] and its absence in humans [13] and in the
GUCY1*B avian model of LCA1 [14] results in severely
compromised vision or blindness at birth. We found that treatment
of the retinas of these animals with a lentivirus carrying a normal
copy of the GC1 gene restored function to the infected
photoreceptor cells, as evidenced by measureable electroretino-
grams and visual behaviors including the optokinetic nystagmus
(OKN) reflex [15]. The benefits of this therapy, which were clearly
detectable in young animals, slowed but did not halt photoreceptor
degeneration. We concluded from these results that corrective
GC1 gene therapy is sufficient to restore function to photorecep-
tors lacking this enzyme and that, if we could prevent the treated
photoreceptor population from degenerating, then we may be able
to reach our current therapeutic goal of inducing lifelong sight in
the GUCY1*B model of LCA1.
Over the past few years, we have been working to develop
lentiviral-based, gene delivery strategies that would allow us to carry
out meaningful studies of the effects of combination gene therapies
on GUCY1*B photoreceptor function and survival. Ideally, the
relative amounts of the proteins generated from thesevectorsshould
be highly consistent among infected cells. Our studies thus far have
revealed that strategies involving delivery of either a mixture of two
lentiviruses [16] or of lentiviruses carrying bicistronic transgenes
constructed using a polio internal ribosome entry site (IRES) [15]
fail to meet our protein expression criterion. Retinas treated with
mixtures of two viruses contained very few infected cells that co-
expressed the proteins encoded by the viruses in the mixture, a
pattern that would be predicted if cells infected by one virus became
refractory to additional infection [17]. In retinas treated withviruses
carrying bicistronic IRES transgenes, the levels of protein produced
from the cistron downstream of the polio IRES were often
undetected in infected cells, a protein expression pattern that has
been observed by others [18,19]. We also examined the protein
expression characteristics of lenitiviral transgenes carrying two
internal promoters, each driving the expression of a single cistron
[16,20]. In general, both of the proteins encoded by the cistrons
were detected in infected cells, but the relative amounts of these
proteins among infected cells were highly variable.
In the present study, we sought to resolve the problems
encountered with these approaches by 1) using two identical
promoters in our dual-promoter lentivectors, 2) inserting an
additional WPRE element between cistrons in our dual-promoter
vectors, and 3) developing vectors carrying bicistronic transgenes
containing the pTV1 viral 2A-like cleavage sequence. Viral 2A-like
cleavage sequences, which were first identified in studies of the foot
and mouth disease virus [21], are short peptide sequences that,
when fused in frame between two cistrons, trigger co-translational
‘ribosomal skipping’, a process that produces equimolar quantities
of the proteins encoded by the transcript. Inclusion of viral 2A-like
cleavage sequences in viral transgenes has been shown to be an
efficient approach for obtaining multiple, functional proteins from a
single vector in vitro and in vivo [22–24]. Our results show that the
protein expression characteristics of the 2A-containing vectors are
superior to those obtained using the other approaches examined in
this study in terms of protein level and the reproducibility of the
protein expression pattern among infected cells. Importantly, we
also show that GC1, delivered to GUCY1*B photoreceptors in the
context of a 2A fusion peptide, is able to restore function to these
cells as evidenced by the appearance of OKN reflexes in the treated
animals. Based on these results, we conclude that 2A-like cleavage
peptides, while not a panacea for all gene therapies, can, with
proper optimization, be used to create bicistronic transgenes that
reliably express both of their encoded proteins. Additionally, these
peptides are small. For these reasons, they should prove to be useful
in the context of many of the viral vectors currently being used in
gene therapy applications.
Results
Design of Bicistronic Lentiviral Vectors
Three different bicistronic transgenes, each encoding GFP and
hemagglutinin (HA)-tagged mCherry (mCherH) fluorescent re-
porter proteins, were cloned into our pFIN lentivector backbone
[20]. The first bicistronic transgene carries two identical
internal EF1 promoters (pFIN-EF1-GFP-EF1-mCherH-WPRE,
Figure 1A), each driving expression of one of the fluorescent
proteins. This transgene was constructed with a promoter that is
ubiquitously expressed and exhibits relatively high activity. It has
been suggested that use of the same promoter in constructing dual-
promoter vectors could lead to inadvertent DNA recombination
during either viral packaging or processing of the viral RNA in the
infected cells [25]; however, we did not see evidence of these
problems when testing dual-promoter vectors carrying identical
photoreceptor-specific promoters [16]. Thus, we chose to examine
the performance of the EF1 dual-promoter transgene, a construct
that would be useful in applications requiring higher protein
expression levels. The second bicistronic transgene was construct-
ed by inserting a second Woodchuck hepatitis posttranscriptional
regulatory element (WPRE) between the upstream cistron and the
second EF1 promoter of the dual EF1 promoter vector (pFIN-
EF1-GFP-WPRE-EF1-mCherH-WPRE, Figure 1B). This modifi-
cation has been shown to improve expression of dual-promoter
vectors carrying two identical promoters [26]. Finally, the third
bicistronic transgene was constructed using the well-characterized
porcine Teschovirus (pTV1) 2A-like cleavage peptide. This peptide
sequence produces two proteins from a single transcript by
inducing co-translational ‘‘ribosomal skipping’’ [27]. During the
‘‘cleavage’’ process, 18 of the 19 amino acids comprising the 2A
peptide, save the C-terminus proline, remain fused to the
upstream peptide. The C-terminus proline remains attached to
the N-terminus of the downstream peptide. This transgene was
created by fusing the cDNAs encoding GFP and mCherH in
frame with the pTV1(2A) sequence (pFIN-EF1-GFP-2A-mCherH-
WPRE, Figure 1C).
Expression of the Bicistronic Transgenes in Transiently
Transfected HEK 293FT Cell Cultures
In this series of experiments, we examined the expression
characteristics of the three bicistronic transgenes in transiently
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and mCherH using both fluorescent microscopy and western
blot. Fluorescent imaging of live cells was used to determine if
GFP and mCherH could be detected in transfected cells and if
the relative amounts of these two proteins were uniform among
transfected cells. Comparisons of GFP (Figure 1D,H,L) and
mCherH (Figure 1E,I,M) expression in transfected cultures
indicated that the levels of GFP in cultured cells expressing the
EF1-GFP-EF1-mCherH transgene were significantly lower than
those expressing the other two transgenes while expression of
mCherH from all three transgenes appeared to be similar.
Examination of the merged GFP and mCherH images
(Figure 1F,J,N) revealed that expression of GFP and mCherH
was most uniform across cells in cultures expressing the EF1-
GFP-2A-mCherH transgene; nearly all of the transfected cells
appeared yellow (Figure 1N). In cultures expressing the EF1-
GFP-W-EF1-mCherH transgene, expression of GFP and
mCherH across cells was moderately uniform; transfected cells
were either green or yellow (Figure 1J). Expression of GFP and
mCherH was least uniform across cells in cultures expressing the
EF1-GFP-EF1-mCherH; in these cultures, transfected cells
ranged from green to red (Figure 1F).
Figure 1. Evaluation of bicistronic transgene expression in transiently transfected HEK 293FT cell cultures. (A–C) Diagrams of the
three bicistronic reporter transgenes analyzed in this study. The solid lines below each transgene indicate predicted mRNA transcripts. Abbreviations:
W - WPRE; H - hemagglutinin tag; EF1 – elongation factor 1 promoter; GFP – green fluorescent protein; mCher – cherry fluorescent protein; 2A -
porcine teschovirus (pTV1) 2A-like cleavage peptide. (D–G), (H–K) and (L–O) are representative images taken of HEK 293FT cell cultures that were
transiently transfected with the lentivector plasmids carrying the indicated transgenes 48 h post-transfection. Image exposure times: GFP images in
panels D,H and L=17 ms; mCherH images in panels E, I and M=4 ms; Hoechst images in panels G, K and O=5 ms. Scale bar in panel D=100 mm.
(P–S) Western blot analyses of the expression of the GFP and mCherH reporter proteins encoded by the bicistronic transgenes. Three replicate HEK
293FT cultures were analyzed for each transgene and one culture was analyzed for each of the control vectors, EF1-mCherH (CH) and EF1-GFP (GFP).
Four identical western blots containing the protein samples were generated and each was probed with an antibody recognizing either
hemagglutinin (P), GFP (Q), 2A (R), or GAPDH (S). GAPDH was used as a protein loading control. (T) Densitometric analyses of GFP and mCherH
protein levels produced from each transgene Significant differences (*p,.05) between the normalized mean GFP and mCherH values are indicated
with brackets. (U) The cleavage efficiency of GFP-2A-mCherH was estimated by expressing the intensities of the cleaved GFP-2A (Q) or mCherH (P)
protein bands as a percentage of total GFP or mCherH immunoreactivity (intensity of the cleaved plus uncleaved protein bands), respectively. Each
estimate is the mean6SD of three samples.
doi:10.1371/journal.pone.0020553.g001
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western blot (Figure 1P-S). Blots were prepared in quadruplicate
and were probed with antibodies against either the HA tag
(Figure 1P), GFP (Figure 1Q), 2A (Figure 1R) or glyceraldehydes
3-phosphate dehydrogenase (GAPDH) (Figure 1S). Examination
of the blots probed with either the HA tag or the GFP antibody
showed that each antibody specifically recognized either mCherH
or GFP, respectively, in protein samples prepared from cultures
expressing either the EF1-GFP-EF1-mCherH or the EF1-GFP-W-
EF1-mCherH transgene. In samples isolated from cultures
expressing the EF1-GFP-2A-mCherH transgene, these antibodies
detected both cleaved and uncleaved GFP-2A-mCherH. Cleaved
GFP-2A was also readily detected using the 2A antibody, which
has been reported to bind to 2A in the context of the cleaved
peptide but not in the context of uncleaved peptide [28]. The
relative amounts of GFP and mCherH produced from each
transgene were determined using a scanning densitometer and the
GFP and mCherH values were normalized to the highest value
obtained for each protein, respectively (Figure 1T). Uncleaved
GFP-2A-mCherH was not included in the determination of the
amount of GFP and mCherH produced in cells expressing the
EF1-GFP-2A-mCherH transgene. An analyses of variance re-
vealed significant differences between transgenes in terms of GFP
expression (F(2,6) =8.92, p=0.016); post hoc analyses using
Tukey tests showed that the relative amount of GFP produced by
the EF1-GFP-EF1-mCherH transgene (M=0.53, SD=0.17) was
significantly lower than that produced from either the EF1-GFP-
WPRE-EF1-mCherH (M=0.94, SD=0.10) or the EF1-GFP-2A-
mCherH (M=0.88, SD=0.11) transgene. No differences were
observed in relative mCherH expression between transgenes
(F(2,6) =3.515, p=0.098). Estimates of the cleavage efficiency of
GFP-2A-mCherH were calculated by expressing the intensities of
the cleaved mCherH (Figure 1P) or GFP-2A (Figure 1Q) protein
bands as a percentage of total HA-tag or GFP immunoreactivity,
respectively. The estimates produced from these calculations were
69%64 (GFP, M6SD; n=3) and 77%63 (HA, M6SD; n=3).
Thus, conservatively the cleavage efficiency of the GFP-2A-
mCherH protein expressed in the HEK 293FT cells was
approximately 73% (Figure 1U).
Expression of the Packaged Viral Bicistronic Transgenes
in 293FT Cell Cultures
This series of experiments was carried out to determine if viral
delivery of the bicistronic transgenes alters the expression
characteristics of the transgenes. HEK 293FT cell cultures were
infected with lentiviruses that carried one of the three bicistronic
transgenes and expression of GFP and mCherH were analyzed
using fluorescent microscopy and western blot. Comparisons of
cultures infected with these viruses showed that the levels of GFP
produced from the EF1-GFP-EF1-mCherH (Figure 2A) and EF1-
GFP-W-EF1-mCherH (Figure 2E) transgenes were significantly
lower than those produced from the EF1-GFP-2A-mCherH
Figure 2. Expression characteristics of lentiviruses carrying the bicistronic transgenes in transduced HEK 293FT cells. (A–D), (E–H)
and (I–L) are representative images of HEK 293FT cell cultures transduced with the indicated lentiviruses 96 h post-transduction. Image exposure
times: GFP images in panels A, E, and I=500 ms; mCher images in panels B, F, and J=180 ms; Hoechst images in panels D, H, and L=5 ms. Scale bar
in A=100 mm. (M–P) Western blot analyses of the expression of the GFP and mCherH reporter proteins in HEK293FT cells transduced with the
lentiviruses. Three replicate HEK 293FT cultures were analyzed for each virus and one culture was analyzed for each of the control viruses, EF1-
mCherH (CH) and EF1-GFP (GFP). Four identical western blots containing the protein samples were generated and each was probed with an antibody
recognizing either hemagglutinin (M), GFP (N), 2A (O), or GAPDH (P). GAPDH was used as a protein loading control. (Q) Densitometric analyses of GFP
and mCherH protein levels produced from each transgene. Normalized mean GFP and mCherH values were compared using paired T-tests and
significant differences between samples (**p,.01, ***p,.001) are indicated with brackets. (R) The cleavage efficiency of GFP-2A-mCherH was
estimated by expressing the intensities of the cleaved GFP-2A (N) or mCherH (M) protein bands as a percentage of total GFP or mCherH
immunoreactivity (intensity of the cleaved plus uncleaved protein bands), respectively. Each estimate is the mean6SD of three samples.
doi:10.1371/journal.pone.0020553.g002
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all three transgenes were similar (Figure 2B, F, J). Merged GFP
and mCherH images (Figure 2C, G, K) were examined to
determine if the levels of expression of these proteins was uniform
across infected cells. Cells infected with pFIN-EF1-GFP-EF1-
mCherH-WPRE virus contained high levels of mCherH and very
little to no detectable GFP (Figure 2C), while those infected with
pFIN-EF1-GFP-2A-mCherH-WPRE virus contained high levels
of both proteins. The few cells infected with pFIN-EF1-GFP-EF1-
mCherH-WPRE virus that did contain trace amounts of GFP did
not appear to express mCherH. Expression of GFP and mCherH
was the least uniform in cultures transduced with pFIN-EF1-GFP-
W-EF1-mCherH-WPRE virus (Figure 2G). The majority of the
cells in these cultures expressed either GFP or mCherH; however,
a subpopulation of the cells was present that co-expressed GFP
and mCherH as evidenced by their yellow hue in the merged
image (Figure 2G, arrows).
The expression of each transgene was also analyzed using
western blot (Figure 2M–P). Blots were prepared in quadruplicate
and were probed with antibodies against either the HA tag
(Figure 2M), GFP (Figure 2N), 2A (Figure 2O) or GAPDH
(Figure 2P). The relative amounts of GFP and mCherH produced
from each transgene were determined using a scanning densitom-
eter and the values were normalized to the highest value obtained
for each protein, respectively (Figure 2Q). Uncleaved GFP-2A-
mCherH was not included in the determination of the amount of
GFP and mCherH produced in cells expressing the EF1-GFP-2A-
mCherH transgene. An analyses of variance revealed significant
differences between transgenes in terms of the amount of GFP
expressed (F(2,6) =315.13, p,0.001); post hoc analyses using
Tukey tests showed that the level of GFP produced by EF1-GFP-
W-EF1-mCherH (M=0.25, SD=0.05) was significantly lower
than that produced by EF1-GFP-2A-mCherH (M=0.95,
SD=0.06). The levels of GFP produced by EF1-GFP-EF1-
mCherH were not detectable on western blots but very low levels
of this protein could be detected in a small minority of the
transduced cultured cells (Figure 2A). No differences were
observed in the levels of mCherH produced by the three
transgenes (F(2,6) =4.22, p=0.072). Estimates of the cleavage
efficiency of GFP-2A-mCherH were calculated by expressing the
intensities of the cleaved mCherH (Figure 2M) or GFP-2A
(Figure 2N) protein bands as a percentage of total HA or GFP
immunoreactivity, respectively. The estimates produced from
these calculations were 96%60.6 (GFP, M6SD; n=3) and
62%62.3 (HA, M6SD; n=3) (Figure 2R).
Expression of the Packaged Viral Bicistronic Transgenes
in Chicken Retina
In this series of experiments, the three bicistronic lentiviruses
were injected into chicken embryos to determine if their expression
characteristics in neural retina were similar to those observed in
HEK 293FT cells. Retinal whole mounts and cryosections were
examined using fluorescent microscopy to determine if GFP and
mCherH could be detected in infected cells and if the relative
amounts of these proteins were uniform among these cells.
Examination of whole mounts (Figure 3A–C) and sections
(Figure 3D–F) of retinas transduced with pFIN-EF1-GFP-EF1-
mCher-WPRE revealed that the relative expression levels of
mCherH were much higher than GFP in these retinas; the few
cells that expressed detectable levels of GFP did not appear to be
co-expressing mCher. Both reporter proteins were detected in
retinas transduced with pFIN-EF1-GFP-WPRE-EF1-mCher-
WPRE; however, the vast majority of the cells expressing this
bicistronic transgene were positive for either GFP or mCher
(Figure 3G–I). We were able to identify scattered groups of cells in
retinal sections that expressed both reporter proteins, but they
were rare and the relative amounts of each protein in these cells
were highly variable (Figure 3J–L). Finally, examination of retinas
transduced with the pFIN-EF1-GFP-2A-mCher-WPRE virus
showed that both of the reporter proteins encoded by this virus
were robustly expressed in these retinas (Figure 3M–R) and that
the relative amounts of these proteins in infected cells were similar.
Together, these results indicate that the expression characteristics
of these three viruses are similar in HEK 293FT and chicken
neural retinal cells.
The variability in the percent of the total area of the retinas of
embryos transduced by the bicistronic viruses precluded the use of
western blot analyses of homogenates of these retinas to determine
the relative expression levels of GFP and mCherH generated from
each of the viral transgenes. However, we were able to examine
the cleavage efficiency of the GFP-2A-mCherH peptide within
individual retinas transduced with pFIN-EF1a-GFP-2A-mCherH-
WPRE virus using western blot (Figure 3S–V). Blots containing
proteins isolated from the retinas of four chickens that had been
treated with pFIN-EF1a-GFP-2A-mCherH-WPRE virus and one
untreated control retina (WT) were probed with antibodies
recognizing either the HA tag (Figure 3S), GFP (Figure 3T), 2A
(Figure 3U) or GAPDH (Figure 3V). Examination of the HA tag
and GFP staining patterns suggested that cleavage of the GFP-2A-
mCherH peptides in infected retinal cells was efficient, results that
were corroborated by the 2A staining pattern (Figure 3U).
Estimates of the cleavage efficiency of GFP-2A-mCherH were
calculated by expressing the intensities of the cleaved mCherH
(Figure 3S) or GFP-2A (Figure 3T) protein bands as a percentage
of total HA or GFP immunoreactivity, respectively (Figure 3W).
The estimates produced from these calculations were 99%60.4
(GFP, M6SD; n=4) and 91%62.6 (HA, M6SD; n=4). These
data show that our bicistronic transgene carrying a 2A cleavage
sequence can be properly transcribed and translated in retinal cells
in vivo.
Expression of 2A Bicistronic Transgenes Encoding
Guanylate Cyclase-1 in Transiently Transfected HEK
293FT Cell Cultures
Prompted by the excellent expression characteristics exhibited
by the 2A containing reporter lentiviruses in vitro and in vivo,w e
constructed a therapeutic 2A vector encoding guanylate cyclase -1
(GC1) and examined its expression in transiently transfected HEK
293FT cells. The transgene we constructed encoded GFP, which
was used to identify transfected or transduced cells, and the gene
encoding GC1that was fused in frame to the 2A peptide
downstream of GFP (Figure 4A). GC1 is a transmembrane protein
that is normally trafficked to the photoreceptor outer segments
where it plays a critical role in recovery of these cells from light
stimulation [12]. We have previously shown that delivery of
bovine GC1 to the photoreceptors of the GUCY1*B chicken
model of LCA1 in the context of an IRES-containing lentiviral
transgene (pTYF-EF1-GC1-IRES-GFP) temporarily reversed
blindness in these animals [15]. In this experiment, we evaluated
the expression of EF1-GFP-2A-GC1 in transiently transfected
293FT cells using fluorescent microscopy and western blot.
Examination of HEK 293FT cell cultures transfected with
pFIN-EF1-GFP-2A-GC1-WPRE DNA (Figure 4B–I) revealed
that all transfected cells expressed GFP and GC1. In normal
photoreceptor cells, GC1 is localized to the membranes of the
outer segments. Thus, we expected that the GC1 produced from
the GFP-2A-GC1 peptide would localize to the membranes of the
transfected cells, which was found to be the case. Immunostained
Lentiviral Delivery of Proteins Using 2A Peptides
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while GFP filled the cell bodies (Figure 4F,H), locations consistent
with the expected subcellular trafficking of these proteins.
Western blot analyses of cells transfected with pFIN-EF1-GFP-
2A-GC1-WPRE showed that the cell lysates contained cleaved
GC1 (Figure 4J) and GFP-2A (Figure 4K,L). Uncleaved GFP-2A-
GC1 peptide was detected but only when the blots probed with the
GFP antibody were highly overexposed. Quantification of the
cleavage efficiency of the GFP-2A-GC1 peptide revealed that it
was 95.3%61.3 (GFP, M6SD; n=3) (Figure 4N).
Evaluation of the Therapeutic Potential of
pFIN-EF1-GFP-2A-GC1-WPRE
In our final experiment, we set out to determine if the integrated
EF1-GFP-2A-GC1 transgene would produce sufficient levels of
GC1 to restore function to the photoreceptors of GUCY1*B
chickens. To be effective, the 2A fusion peptide expressed in
photoreceptors needed to be cleaved efficiently and the resulting
GC1 enzyme had to be properly trafficked to the outer segments of
the photoreceptors. Stage 8–10 GUCY1*B embryos were injected
with pFIN-EF1-GFP-2A-GC1-WPRE, hatched, and tested weekly
for the presence of the optokinetic visual response (OKN) until
they reached 5 weeks-of-age. The OKN responses of 7 treated
animals were evaluated once a week for five weeks by holding the
animals in the center of rotating platform that supported high
contrast, visual stimuli consisting of vertical square wave gratings
with spatial frequencies of 0.065 or 0.26 cycles?degree
21 that
corresponded to bar widths of 5 or 1.25 cm, respectively
(Figure 5A). These responses were compared to those obtained
from wild-type and untreated GUCY1*B animals. OKN responses
are driven primarily by the peripheral regions of the retina
[29,30], and unlike mammalian OKN responses, these responses
in chickens are monocularly driven, the responses to clock-wise
and counter-clockwise rotation of the visual stimuli being driven
by the left and right eyes, respectively [31]. The OKN responses of
the wild-type chickens were robust, characterized by well-defined
lateral head movements synchronized with the speed of rotation of
the visual stimulus (Video S1), while the untreated GUCY1*B
Figure 3. Expression characteristics of bicistronic lentiviruses in chicken retina. Lentiviruses were injected and retinal whole mounts and
sections were imaged as described in the methods. (A–C) Whole mount and (D–F) representative section of a retina treated with pFIN-EF1-GFP-EF1-
mCher-WPRE virus show robust expression of the downstream reporter (mCher). The upstream reporter (GFP) was either weakly expressed (A) or not
detected (D). (G–I) Whole mount and (J–L) representative section of a retina treated with pFIN-EF1-GFP-WPRE-EF1-mCher-WPRE virus revealed that
both reporter proteins were expressed in the treated retina but that only one of the reporter proteins could be detected in the majority of cells
expressing the transgene. (M-O) Whole mount and (P–R) representative section of a retina treated with pFIN-EF1-GFP-2A-mCher-WPRE show robust
co-expression of both reporter proteins in transduced cells. Scale bars in A and D=50 mm. (S–V) Western blot analyses of the retinas of four chickens
treated with pFIN-EF1-GFP-2A-mCher(H)-WPRE virus. Four replicate blots containing proteins extracted from the retinas were probed with antibodies
to either hemagglutinin (S), GFP (T), 2A (U), or GAPDH (V). (W) The cleavage efficiency of GFP-2A-mCherH was estimated by expressing the intensities
of the cleaved GFP-2A (T) or mCherH (S) protein bands as a percentage of total GFP or mCherH immunoreactivity (intensity of the cleaved plus
uncleaved protein bands), respectively. Each estimate is the mean6SD of three samples.
doi:10.1371/journal.pone.0020553.g003
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treated embryos that hatched produced OKN responses
(Figure 5B; Video S3). A repeated measures ANOVA was used
to examine the effects of stimulus type on the magnitude of the
OKN responses over time. The results indicated that the response
magnitude significantly decreased over the course of the 5-week
test period (F(5,60) =5.0; p=0.0007), in the absence of a main
effect of stimulus type.
At the end of the 5-week testing period, we analyzed whole
mounts of treated animal’s retinas to obtain an estimate of the
efficiency of our viral treatment. Our viral delivery method leads
to infection of progenitor cells in the developing neural tube, some
of which generate the neural retina. Examples of the viral
transduction patterns produced in the retinas of our treated
animals are shown in Figure 5 (C,D). Unlike the transduction
pattern produced following subretinal delivery of viral vectors that
is characterized by one large, contiguous population of infected
cells, the transduction pattern produced following neural tube
delivery of viral vectors is characterized by numerous scattered
groups of infected cells that are distributed across the entire retina.
The estimates of the total area transduced by the virus in the
retinas shown in Figure 5 were 7% and 16%. These retinas
belonged to the animal in the treated group whose OKN responses
were assigned a rating of 3 throughout the entire 5-week test
Figure 4. Evaluation of the expression characteristics of the EF1-GFP-2A-GC1 transgene in transiently transfected HEK 293FT cells.
(A) Diagram of the EF1-GFP-2A-GC1 transgene. (B–E and F–I) Representative images of transiently transfected HEK 293FT cell cultures expressing
EF1-GFP-2A-GC1 imaged 48 h post-transfection. Scale bars shown in B and F equal 100 and 50 mm, respectively. (J–M) Western blot analyses of HEK
293FT cells transiently transfected with pFIN-EF1-GFP-2A-GC1-WPRE (n=3) probed for GC1 (J), GFP (K), 2A (L), and GAPDH (M). Non-transfected HEK
293FT cells (NT), HEK 293FT cells transfected with pFIN-EF1-GC1-IRES-GFP (IRES), and HEK 293FT cells transfected with pFIN-EF1-GFP-WPRE served as
controls. GAPDH served as a loading control. (N) The cleavage efficiency of GFP-2A-GC1 was estimated by expressing the intensities of the cleaved
GFP-2A (K) protein bands as a percentage of total GFP immunoreactivity (intensity of the cleaved plus uncleaved protein bands). The estimate is the
mean6SD of three samples.
doi:10.1371/journal.pone.0020553.g004
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animals whose OKN responses declined over the test period
ranged from 3–7%. The strength and stability of these responses
over time were very similar to those that we observed in animals
treated with our IRES GC1 bicistronic vectors [15]. Overall, the
results of the current study are encouraging because they show
that the GC1 encoded by the 2A transgene is functional and that
visual responses can be generated by a relatively small number of
functioning photoreceptor cells. Importantly, they also suggest that
relatively small increases in the total number of transduced
photoreceptors in treated retinas could significantly increase the
strength and stability of visual responses in treated animals.
Discussion
The results of this study clearly show that it is possible to obtain
consistent expression of two proteins from viral transgenes
consisting of two cistrons joined in frame by the pTV1 viral 2A-
like cleavage sequence. Importantly, the results of our study
establish the therapeutic potential of this specific vector design. We
found that we were able to reverse blindness in GUCY1*B
chickens by treating them with pFIN-EF1-GFP-2A-GC1-WPRE
virus, a finding that indicates that the GC1 encoded by this
transgene was properly processed and was expressed in sufficient
amounts in photoreceptor cells expressing the transgene to support
the function of these cells. Together, these results highlight the
potential of this vector design to serve as a platform for
development of combination therapies designed to enhance or
prolong the benefits of corrective gene therapies.
The cleavage characteristics and small sizes of 2A-like cleavage
sequences make them particularly useful in developing multi-
cistronic viral vectors [22]. Since the proteins encoded by
transgenes containing 2A sequences are translated from one
transcript, co-translational cleavage of these polypeptides is
expected to produce equimolar quantities of the proteins [32–
34]; however, proper cleavage and post-translational processing of
the proteins does not always occur as expected. The cleavage
efficiency of the polypeptide can be influenced by the nucleotide
sequences flanking 2A and the order of the cistrons in the
transgene relative to the 2A sequence [23,28,35–37]. The order of
the cistrons relative to the 2A sequence can also alter post-
translational processing and intracellular trafficking of the proteins
encoded by the cistrons [28,36,37]. The small size of the 2A
sequence is a second advantage of this technology, a feature that is
particularly attractive when constructing multicistronic transgenes
using viral vectors with limited cargo capacity.
Two counter indications to using 2A peptides are poor cleavage
efficiency of the translated polypeptide and disruption of function
of the upstream protein by the residual 2A peptide that remains
fused to its C-terminus. Poor cleavage efficiency could lead to
accumulation of significant amounts of uncleaved protein and the
formation of toxic protein aggregates in cells expressing the
transgene. Strategies that have been reported to significantly
improve cleavage efficiency of 2A polypeptides include insertion of
Figure 5. Analyses of the optokinetic (OKN) reflex responses of GUCY1*B chickens treated with pFIN-EF1-GFP-2A-GC1-WPRE virus.
(A) Frame of OKN video showing the optokinetic testing apparatus. Videos of the OKN responses obtained from wild-type (Video S1), untreated
GUCY1*B (Video S2) and treated GUCY1*B chickens (Video S3) are provided as supplemental data. (B) Summary of OKN responses obtained from
seven treated GUCY1*B animals. The plotted values are the means6SEM of the average OKN responses obtained in response to either the large bar
(LB) or small bar (SB) stimuli. (C, D) Whole mounts of the left (C) and right (D) retinas of a 5-week-old animal that had been treated with the virus. The
percentage of the total retinal area infected by the virus was estimated using ImageJ software. The orientation of the retinas (D-dorsal; T-temporal)i s
indicated in panel C.
doi:10.1371/journal.pone.0020553.g005
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acid spacer upstream of the GSG linker- 2A sequence [38,39]. To
determine if addition of a furin site to our EF1-GFP-2A-mCher
transgene could increase cleavage of the 2A polypeptide, we
constructed and compared the cleavage efficiency of GFP-furin-
2A-mCher to that of GFP-2A-mCher. EF1-GFP-Furin-2A-mCher
was constructed by inserting nucleotides encoding furin binding
site (RAKR) upstream of the GSG-2A sequence. Western blot
analyses of HEK 293FT cells expressing these transgenes revealed
that addition of the furin site interfered with 2A cleavage (Figure
S1). Very little of the polypeptide translated from the EF1-GFP-
Furin-2A-mChe transgene was successfully cleaved compared to
that translated from the EF1-GFP-2A-mCher transgene. It is
possible that inclusion of an additional amino acid spacer between
the furin site and the GSG linker-2A site would improve cleavage
efficiency of our transgenes. We have not examined this possibility.
Addition of a furin cleavage site upstream of the 2A peptide, the
cleavage of which would effectively remove the 2A peptide
sequence from the C-terminus of the protein encoded by the
upstream cistron, has also been reported to improve the function
of this protein [38]. To minimize disruption of function of the
upstream protein we routinely place cistrons that encode proteins
amenable to C-terminus modifications upstream of the 2A peptide
sequence in our vectors. Our and other investigators experiences
with 2A sequences clearly indicate that it is important to examine
the performance of each 2A construct in the cellular context in
which they will be used.
In addition to the 2A transgenes examined in this study, we also
examined the expression characteristics of bicistronic transgenes
that were constructed using two independent EF1 promoters. Our
decision to construct and examine the expression characteristics of
the pFIN-EF1-GFP-EF1-mCher-WPRE vector in this study was
prompted by the results of a previous study in which we found that
the expression levels of two proteins encoded by dual-promoter
vectors carrying two identical copies of a single photoreceptor-
specific promoter, while not equal, were much higher than those
obtained from IRES-containing transgenes [16]. The results of our
analyses of the expression of pFIN-EF1-GFP-EF1-mCher-WPRE
lentivirus in transduced HEK 293FT cells (Figure 2A–D) and in
retinas (Figure 3A–F) were surprising because very little to no GFP
expression was detected in infected cells. In retina, the GFP that
was detected was not co-localized with mCher. Interestingly,
inclusion of an additional WPRE element immediately after the
upstream cistron (EF1-GFP-WPRE-EF1-mCher) did not signifi-
cantly improve expression of GFP in transduced cells (Figure 2E–
H) or retinas (Figure 3G–L). In fact, in our hands this
modification, which was previously reported to enhance expres-
sion of both cistrons in a dual-promoter lentivector carrying
identical hSynapsin promoters [26], produced a lentivirus that
expressed only one or the other cistron in the vast majority of the
infected cells. This unique protein expression pattern appeared to
be observed only when the vectors were delivered in viral form.
Both reporter proteins were co-expressed in HEK 293FT cells
transfected with either plasmid DNA. One possible explanation for
this observation is suggested by the expression characteristics of
two of our dual-promoter lentivectors. When the EF1 promoters
(1446 bp) used in this study to construct the EF1-GFP-EF1-
mCher-WPRE transgene are replaced with either two rhodopsin
kinase (297 bp) or interphotoreceptor retinol binding protein
(262 bp) promoters, the reporter proteins are co-expressed in the
retinal photoreceptors infected by the lentiviruses [16]. While
untested, it is possible that the size of the EF1 promoter, which is
approximately 5 times larger than either of the photoreceptor
promoters, increases the probability of deletion of one of the
cistrons during either viral packaging or reverse transcription of
the viral RNA genome in infected cells prior to integration via
homologous recombination [40–42]. Although the results obtained
from our EF1 dual-promoter lentiviruses were undesired in our
experiments, exclusive expression of either cistron of a bicistronic
vector in transduced cells may be useful in some experimental or
therapeutic applications.
One of the major focuses of our research program is to develop
therapies for human LCA1. The animal model that we use in our
studies is the GUCY1*B chicken, which is currently the only
animal model for this disease that models both the genotype and
phenotype of human LCA1. We have previously demonstrated
that GC1 corrective gene therapy is sufficient to restore function to
photoreceptor cells and reverse blindness in these animals [15], a
finding corroborated by the results of this study. The primary
difference between the lentiviral vectors used in these two studies
was in the design of the bicistronic GC1 transgenes they carried.
The bicistronic transgene used in our previous study contained an
IRES element. In the current study, this element was replaced
with a 2A-like cleavage sequence. Both bicistronic vectors
produced sufficient amounts of GC1 to restore function to
GUCY1*B photoreceptors and visual behavior to treated animals,
but only the 2A transgene consistently expressed both of the
encoded proteins. Importantly, our results indicate that the proline
residue retained on the N-terminus of GC1 following co-
translational ‘cleavage’ of the 2A peptide does not negatively
affect the activity of the GC1 protein encoded by the GFP-2A-
GC1 transgene.
To date, we have not yet achieved permanent vision restoration
in GUCY1*B animals using corrective gene therapy alone, a
problem that plagues many investigators working to design
therapies to treat aggressive inherited photoreceptor diseases
caused by mutations in genes expressed in these cells [3,43,44]. In
the current study, we noted that higher percentages of retinal
transduction with our GC1 vector were positively correlated with
the strength of the visual responses exhibited by the animal and the
duration of the benefits of the treatment. Our successes using
corrective GC1 therapy alone suggest that it might be possible to
achieve life-long restoration of vision in our model system by
simply increasing the number of photoreceptors expressing the
GC1 transgene. The fraction of the photoreceptor cell population
that must be treated to achieve this outcome is unknown, but it is
likely that the spatial relationships of the treated cells to other
treated and untreated cells in the retina will have an impact on this
value. We are interested in determining this value since it would
provide a useful benchmark for comparing the effectiveness of
different treatment strategies. A second approach that may lead to
life-long vision restoration in our model would be to combine
delivery of GC1 to the photoreceptors with delivery of additional
therapeutic molecules (e.g. neurotrophic or anti-apoptotic factors)
to enhance survival of the photoreceptors. The results of this study
show that we will be able to successfully deliver combination
therapies to photoreceptors and other retinal cells using bicistronic
transgenes carrying 2A-like cleavage sequences. Efforts are
currently underway to determine if combination therapies can
improve treatment outcomes in our model of LCA1.
In summary, we examined the expression of three different
bicistronic lentivectors in HEK 293FT cells and in neural retina
and found that the lentivectors carrying transgenes containing 2A-
like cleavage peptides were the only ones that reliably expressed
both of the proteins encoded by the transgene and expressed them
in a highly reproducible manner among infected cells. Since we
were able to restore vision in GUCY1*B chickens using the 2A
vector encoding GC1, our laboratory has now begun to develop
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delivery with delivery of additional therapeutic proteins can
permanently restore vision to these animals. While we use
lentivectors in our studies, 2A-like cleavage peptides should prove
valuable in any therapeutic or biotechnological application
requiring co-expression of multiple proteins in targeted cells.
Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. All
animal protocols were approved by the University of Florida
Institutional Animal Care and Use Committee (Approval
201004563) and adhered to the policies outlined in the Guide
for the Care and Use of Laboratory Animals.
Construction of Vectors
pFIN-EF1-GFP-EF1-mCherH-WPRE. pFIN-WPRE [16] was
digested with NheI. GFP was amplified using PCR and a sense
primer containing NheI and BsiWI and an antisense primer
containing MluI and NheI. The PCR product was ligated into
pFIN-WPRE at the NheI site to create pFIN-GFP-WPRE. This
vector was then linearized using NotI and the EF1 promoter,
which was amplified using sense and antisense primers containing
NotI, was ligated into pFIN-GFP-WPRE to create pFIN-EF1-
GFP-WPRE. A second EF1 promoter was amplified using a sense
primer containing BsiWI and an antisense primer containing
PacI and MluI sites and was ligated into pFIN-EF1-GFP-WPRE
using BsiWI and MluI. Finally, hemagglutinin (HA)-tagged
mCherry (mCherH) was created using PCR primers containing
PacI sites and was ligated into the linearized pFIN-EF1a-GFP-
EF1-WPRE to create the final construct. The antisense primer
included the HA tag that was fused in frame to mCher
immediately upstream of the stop codon. It was necessary to
tag mCher with an epitope to which antibodies exist since we and
others [45] have found that the antibodies that are currently
available for mCher fail to detect this protein on western blots.
pFIN-EF1-GFP-WPRE-EF1-mCherH-WPRE. pFIN-EF1-GFP-
EF1-mCherH-WPRE was linearized using BsiWI. WPRE was
amplified using sense and antisense primers containing BsiWI
sites and WPRE was ligated into the linearized backbone to
create pFIN-EF1-GFP-WPRE-EF1-mCherH-WPRE.
pFIN-EF1-GFP-2A-mCherH-WPRE. pFIN-EF1-GFP-WPRE
[16] was digested with NheI to remove GFP. GFP-2A-mCherH
was created using a three-step PCR strategy described by
Symczak et al [46] that included the addition of a GSG linker
sequence upstream of the PTV1 2A peptide sequence. The final
set of primers used to amplify GFP-2A-mCherH contained NheI
sites that permitted it to be ligated into the NheI site in the pFIN-
EF1a-WPRE backbone to create the final vector.
pFIN-EF1-GFP-Furin-2A-mCher-WPRE. This vector was
created using the same strategy as that used to construct pFIN-
EF1-GFP-2A-mCherH-WPRE except that the primers used to
amplify GFP included sequence encoding the furin cleavage site
(RAKR) that was inserted in frame just upstream of the GSG
linker.
pFIN-EF1-GFP-2A-GC1-WPRE. The cDNA encoding
bovine GC1 was removed from pBSII SK+-GC1 [15] using
SpeI and KpnI and was ligated into our pFIN-WPRE backbone
that had been digested with SpeI and KpnI. EF1 was amplified
using sense and antisense primers containing NotI sites and was
ligated into the NotI site in pFIN-GC1-WPRE. The resulting
vector, pFIN-EF1-GC1-WPRE, was then digested with NheI and
StuI, the StuI site being located approximately 700bp downstream
from the start codon of the GC1 open reading frame. GFP-2A-
GC1 (5’ 700 bp) was amplified using the three-step PCR method.
The final sense and antisense primers used to amplify the GFP-2A-
GC1 (5’ 700 bp) fragment contained NheI and StuI sites,
respectively. GFP-2A-GC1 was then ligated into pFIN-EF1-
GC1-WPRE to create pFIN-EF1-GFP-2A-GC1-WPRE.
Lentiviral Packaging
The lentiviral vectors were packaged into lentivirus pseudotyped
using vesicular stomatitis virus G (VSV-G) glycoprotein using a
three plasmid packaging system as previously described [20]. Viral
titers were estimated using a Lenti-X qRT-PCR kit (Chemicon,
Billerica, MA) and typically averaged 2610
12 viral genomes per
ml.
Cell Culture and In Vitro Transfection and Transduction
HEK 293FT cells were grown and maintained in Dulbecco’s
Modified Eagle high glucose media containing 4.5 mg/ml D-
glucose, L-glutamine and 0.11 mg/ml sodium pyruvate (Invitro-
gen, Carlsbad, CA) to which was added 10% fetal calf serum,
50 U/ml penicillin G, 50 mg/ml streptomycin, and 500 mg/ml
geneticin. The cells were transiently transfected with plasmid DNA
using Superfect (Qiagen, Valencia, CA) according to the
manufacturer’s instructions. In brief, 200,000 cells were seeded
per well of gelatin-coated 6 well plates 24 h prior to transfection
and were transfected with a mixture of 2.0 mg of DNA and 10 ml
of Superfect per well. The transfected cells were allowed to
proliferate for 48 h. To analyze the performance of the vectors
when delivered as viral particles, HEK 293FT cells were plated as
described above and were exposed to approximately 2610
9 viral
particles for 72 h prior to analysis. Transfected or transduced cells
were either harvested for Western blot analyses in SDS sample
buffer supplemented with protease inhibitor cocktail (Roche,
Indianapolis, IN) or were examined directly using a Zeiss
AxioCam MRm digital camera system (Carl Zeiss Microimaging,
Inc.,Thornwood, NY). GFP was detected using a narrow-band
GFP filter set 41020 (Chroma Technology Corp, Bellows Falls,
VT) and mCher was detected using a Chroma custom filter set
that consisted of an exciter ET572/35, an emitter ET632/60, and
a beamsplitter (Chroma Technology Corp, Bellows Falls, VT). For
comparison purposes the exposure times used to photograph each
reporter were kept constant between constructs. Hoechst (Molec-
ular Probes Inc., Eugene, OR) was added to live cells for 3 min
before analysis to visualize nuclei.
Viral Injections of Chicken Embryos
All eggs used in this study were obtained from our wild-type
Rhode Island Red and our GUCY1*B breeding colonies that we
maintain at the University of Florida. Lentiviruses were injected
into chicken embryos (stage 8–10) on embryonic day 2 (E2) as
previously described [15]. Approximately 345 nl of virus was
injected into the anterior region of the developing embryonic
neural tube. The treated eggs were then sealed and incubated to
E20 at which time the embryos were either sacrificed and the
retinas were harvested for analyses or were hatched using our
previously described protocol [15].
Behavioral Analyses
The optokinetic nystagmus (OKN) responses, which are
reflexive visual responses driven primarily by visual stimuli
processed by the peripheral regions of the retina, were evaluated
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methods [15]. Two high contrast, vertical square wave grating
stimuli with spatial frequencies of 0.065 or 0.26 cycles?degree
21
(bar widths of 5 cm and 1.25 cm, respectively) were used to elicit
the responses. The behaviors were recorded using a digital camera
(Canon Vixia HF20 HD video camera; http://www.usa.canon.
com). The recorded behaviors were analyzed using a zero-three
point scoring system: zero, no OKN response; one, inconsistent or
unidirectional responses to the lower spatial frequency grating;
two, consistent bidirectional responses to the lower spatial
frequency grating; three, consistent bidirectional responses to the
higher spatial frequency grating. The scores of the OKN responses
for the right and left eyes of each animal obtained using the 5 or
1.25 cm bar stimuli were averaged to obtain the OKN response
score for each stimulus on each test day.
Retinal Whole-Mounts and Immunohistochemistry
Retinal whole mounts and immunohistochemistry were carried
out as previously described [20]. The GFP and mCher reporter
proteins were detected using either native fluorescence or
immunohistochemistry. GFP and mCher native fluorescence was
detected in retinal whole mounts and sections using the
appropriate fluorescence filters and documented using a Zeiss
AxioCam MRm digital camera. For immunohistochemistry,
retinal whole mounts or cryosections (10 mm) were probed with
a polyclonal rabbit anti-GFP antibody (1:2000, overnight, kindly
provided by W. Clay Smith, University of Florida, Gainesville, FL)
and counterstained with 49,6-diamidino-2-phenylindole (DAPI)
where indicated. The primary antibody was detected using Alexa
Fluor 488 (1:500, Invitrogen). Zeiss filter set 02 was used to
visualize DAPI-stained cell nuclei. To visualize GFP expression in
retinal whole-mounts, retinas were incubated with a biotinylated,
anti-rabbit secondary antibody and were processed using a
Vectastain ABC kit and a 3,39-diaminobenzidine (DAB) substrate
kit for peroxidase (Vector laboratories, Inc., Burlingame, CA). The
percent transduction of the retinal whole mounts was determined
using the analyze particles feature of ImageJ version 1.44 h.
Western Blot
Western blot analyses of the proteins expressed in transfected or
transduced HEK 293FT cells and in transduced retinas were
performed as previously described [47]. In brief, protein samples
(1 mg of total transfected cell lysate, 15 mg of total transduced cell
lysate, or 30 mg retina lysate) were separated on precast, gradient
4–12% polyacrylamide gels and transferred to PVDF membranes
using an i-Blot transfer apparatus according to the manufacturer’s
instructions (Invitrogen, Carlsbad, CA). The blots were prepared
in quadruplicate permitting each blot to be probed with a single
antibody. Antibodies recognizing GFP, 2A, hemagglutinin, GC1,
or GAPDH were used to probe the blots. After blocking the
membranes in 5% milk/Tris Buffered Saline (TBS) for 1 h, the
blots were incubated with primary antibody overnight at 4uC with
gentle shaking. After three 10 minute washes in TBS, blots were
incubated in secondary antibody diluted 1:5000 in 5% milk/TBS
for two hours at room temperature. The secondary antibodies
used in this study were anti-chicken (GeneTex, Irvine, CA), anti-
rabbit and anti-mouse (Cell Signaling Technology, Inc., Danvers,
MA), and anti-rat (Sigma-Aldrich, St. Louis, MO). The blots were
then washed and signals were visualized with ECL (Amersham,
UK). Films were scanned using a GS-800 calibrated densitometer
(BioRad, Hercules, CA) and the signals were quantified using
Scion Image software (Scion Corp., Frederick, MD). For each
bicistronic transgene, the densities of the mCherH and GFP-2A
protein bands detected in the samples were determined and then
normalized to the highest mCherH or GFP-2A sample value,
respectively, which was assigned a value of 1.0. The relative levels
of GFP-2A and mCherH produced by the transgenes were
compared using analyses of variance and Tukey post hoc tests
when appropriate (SigmaStat v2.03, Aspire Software Internation-
al, Ashburn, VA). Graphs were generated using GraphPad Prism
5.0 (GraphPad Software, Inc., La Jolla, CA).
Primary Antibodies
The primary antibodies used in the western blot experiments
were chicken anti-GFP (1:3000, Abcam, Cambridge, MA,
Western blot analysis), rabbit anti-2A (1:2000, Millipore, Billerica,
MA), rabbit anti-GC1 (1:500, kind gift from Dr. A. Yamazaki), rat
anti-hemagglutinin, High Affinity (1:5000, Roche, Indianapolis,
IN), and mouse anti-GAPDH (1:5000, Encor, Gainesville, FL).
Rabbit anti-GFP (1:2000, kind gift from Dr. W. Clay Smith) was
used to stain retinal whole mounts.
Supporting Information
Figure S1 Cleavage of GFP-2A-mCher and GFP-furin-2A-
mCher polypeptides in transfected HEK 293FT cells. (A, B)
Diagrams of the EF1-GFP-2A-mCher and EF1-GFP-furin (F)-2A-
mCher transgenes. (C) Western blot showing cleavage of EF1-
GFP-2A-mCher (-F) and EF1-GFP-F-2A-mCher (+F) transgenes.
The blot was probed with an antibody against GFP that
recognized both the cleaved and uncleaved polypeptides. The
amount of total protein loaded per lane was either 20 or 50 mg.
(TIF)
Video S1 Optokinetic behavior of 8-day-old wild-type chicken.
The responses shown were elicited by a high-contrast vertical
square wave grating with a spatial frequency of 0.26 cycles?de-
gree
21 (bar width 1.25 cm). Reflexive head movements charac-
teristic of the optokinetic response in birds were observed when the
stimulus was rotated either clockwise or counter clockwise. No
optokinetic responses were elicited by the white control stimulus
(MP4)
Video S2 Optokinetic behavior of 8-day-old untreated GU-
CY1*B chicken. No responses were elicited by either of the high-
contrast vertical square wave grating stimuli. The stimuli used in
this particular test were a high-contrast vertical square wave
grating with a spatial frequency of 0.26 cycles?degree
21 (bar width
1.25 cm) and a solid white stimulus.
(MP4)
Video S3 Optokinetic behavior of 8-day-old GUCY1*B chicken
that had been treated with pFIN-EF1-GFP-2A-GC1-WPRE
lentivirus on embryonic day 2. This treated animal, unlike
untreated animals, exhibited a robust, optokinetic response that
was assigned a score of 3.0. Reflex responses were elicited by the
high-contrast vertical square wave grating (bar width 1.25 cm)
when rotated in either clockwise or counter clockwise. No
responses were elicited by the solid white control stimulus.
(MP4)
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